Danaher stock: CEO targets faster growth beyond 2027 base

Published on 11/11/2026 at 16:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Danaher stock traded at 212.80 euros on Lang & Schwarz Wednesday. CEO Julie Sawyer Montgomery is targeting faster growth through execution and innovation.

Danaher maps its next growth phase

CEO Julie Sawyer Montgomery outlined four priorities at the UBS Global Healthcare Conference.
Management sees commercial execution, innovation, talent and capital allocation as the main growth levers.
Bioprocessing reshoring is expected to contribute more materially from 2028 onward.

Danaher Corp., US2358511028, Illustration mit AI erstellt.

At the UBS Global Healthcare Conference on Monday, November 9, Danaher outlined a growth strategy aimed at moving beyond its current mid-single-digit core-growth base. The presentation was reported by Investing.com.

Four levers shape the strategy

CEO Julie Sawyer Montgomery said Danaher is focusing on commercial execution, innovation, talent and capital allocation. The plan includes broader cross-selling between operating companies and more consistent use of the Danaher Business System after acquisitions.

Management sees core growth excluding respiratory revenue of 4% to 5% as the starting point for 2027. The longer-term ambition is to move toward high-single-digit growth through stronger customer coverage, new products and market-share gains.

Longer-term opportunities remain

Montgomery highlighted biologics, biosimilars, AI-enabled drug discovery and blood-based Alzheimer's testing as structural opportunities. She also described reshoring as a potential bioprocessing market opportunity, while saying the main revenue impact is more likely to emerge from 2028 onward.

Danaher stock traded at 212.80 euros on Lang & Schwarz at 16:09 CET on Wednesday, November 11, 2026. That was 1.19% above the 210.30-euro quote cited in the previous report at 12:37 CET on the same day; this report-to-report comparison is separate from a Xetra session comparison.

What investors should watch next

The key test is whether Danaher converts its preliminary growth base into higher reported performance. Investors will be watching for sustained share gains, stronger core growth and evidence that commercial initiatives translate into profitable expansion.